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Abstract
Aim: The aim of this retrospective study was to analyse 
the false positive rate of suspicious non palpable breast lesions 
detected by ultrasonography and mammography.
Method: The data was collected from the first seven years 
(2000-2007) since the set up of the Breast Unit in Malta. 
Results: The results showed that the false positive rate 
for suspicious breast lesions detected by ultrasound and 
mammography were 84% and 57.6% respectively. The overall 
false positive rate was 62.5%.
Conclusion: The overall false positive rate for suspicious 
breast lesions detected by both radiographic modalities is high 
in our unit when compared to that of other centres. Suggestions 
for improvement are discussed.
                                
Introduction
Screening mammography has become commonplace in the 
routine health management of women world-wide. More than 
600,000 women undergo breast biopsies globally annually. 
20-40% of these are for non-palpable breast lesions.1 The early 
detection and management of non palpable breast lesions 
suspected to be malignant has therefore become an important 
issue.   Guide wire localization (GWL) followed by excision was 
introduced in 1985, and has remained the preferred technique 
for treatment of non palpable mammographically (mammo) 
and ultrasonographically (US) detected breast lesions.1 This 
method has remained the gold standard against which more 
modern biopsy techniques of suspicious non palpable breast 
lesions are compared.
In Malta, the Breast Clinic was set up in January 2000, 
initially at St. Luke’s Hospital, now at Mater Dei Hospital. On 
average, 25 new cases are seen per week, including symptomatic 
and screen detected problems. This results in approximately 
1300 new cases annually.
Aim
This retrospective single centre study analysed false positive 
rates of suspicious non palpable breast lesions detected on 
ultra sound and mammography for the period January 2000 
to December 2007. Female patients who were found to have 
suspicious breast lesions on routine or screening mammography 
or ultrasonography requiring localisation biopsy were studied. 
The local experience, trends and outcomes were analysed.
Methods
Patient records for those patients attending the Breast 
Clinic for the period January 2000 to December 2007 were 
retrospectively reviewed after obtaining a list of patients who 
underwent guide wire localization (GWL) of impalpable breast 
lesions at the Imaging Department. The patients seen at the 
Breast Clinic and included in this study were all operated by 
the Breast Care Team. Data regarding patient characteristics, 
clinical assessment, type of localisation performed, histology 
of biopsy specimen and further management performed was 
collected and entered into an Excel spreadsheet.
GWLs were all performed by 3 experienced radiologists 
with an interest in breast disease. Using Kopan’s Hook, US 
localisation was done by means of a hand held US probe while 
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mammographic localisation was performed using the grid 
technique. Two cohorts were identified: those with suspicious 
impalpable lesions detected by mammography (mammo GWL 
group) and a second cohort with suspicious non palpable lesions 
detected by US (US GWL group).
Definitions
A redo GWL implies that the radiograph of the biopsy 
specimen did not include the suspect lesion or microcalcifications 
seen in the original radiograph, or else that repeat mammogram 
during follow up showed the same lesions thereby necessitating 
a repeat localisation.
A lesion on ultrasound was regarded as suspicious if it 
was hypoechoic with irregular outlines and/or dorsal acoustic 
shadowing.
A lesion on mammography was regarded as suspicious if 
it showed a cluster of fine microcalcifications or a spiculated 
lesion.
An adequate biopsy specimen implies the presence of in situ 
or invasive malignancy .
A true positive implies that the suspicious lesion on US 
or mammogram was confirmed to be malignant on histology. 
A false positive implies that the lesion visualised on US or 
mammography was regarded as suspicious and proven to be 
benign on histology. 
Statistical analysis
Medians as well as means were used as some data variables 
were moderately skewed. T-tests were used to compare means. 
Fischer’s and χ2 tests were used to compare proportions. A p 
value ≤0.05 was considered statistically significant.
Results
A national breast screening programme had not been set up 
when this study was conducted. Breast screening is offered to 
“high risk” women referred by general practitioners to the Breast 
Clinic. A considerable number of women undergo opportunistic 
breast screening at private clinics and are referred to the Breast 
Clinic for surgery. All suspicious mammograms are reviewed 
at the multi-disciplinary breast meeting and the decision to 
perform GWL is taken there. A substantial number of women 
who have had private mammograms are told that they require 
biopsy and this decision is respected by the team.
One hundred and twenty-six patients underwent GWL 
of suspicious non palpable breast lesions at the Breast Unit 
between January 2000 and December 2007.
One hundred and one cases underwent a mammographically 
guided localisation procedure. The remaining 25 patients had 
US detected suspicious lesions and localisation was therefore 
performed under US guidance.  Overall,  136  GWLs  were  performed 
(Table 1). Figure 1 demonstrates the trend regarding type and 
number of GWLs performed during the 7 year study period. This 
graph shows that during the study period there was a progressive 
increase in the number of mammographic GWLs performed but 
a slow increase in the number of ultrasonographic GWLs . The 
maximum number of GWLs was performed in 2006 followed 
by a sharp drop in 2007.
Table 2 summarises the patient characteristics of both 
cohorts.
In the mammo GWL group, 10 extra procedures were 
performed. Four patients required simultaneous bilateral 
localisations, and another 5 patients needed a redo GWL, one 
of which had 2 redos. The mammo GWL had a redo rate of 5.4% 
compared to the US group which had a redo rate of 0% (p=ns).
The absence of redoes in the US group is due to the fact that the 
specimen is not subjected to US analyses. Four patients (3.9%) 
in the mammo GWL cohort required simultaneous bilateral 
localisations. Therefore the redo mammo GWL accounted for 
5.4% of this group and 4.4% of the total GWL procedures. Table 3 
demonstrates the clinical features of the 2 groups of patients.
Mammo GWL group
Twenty-three (22.7%) out of 101 patients who had a routine/
screening mammography had an US of the breast performed 
at the same time or soon after. Sixteen of these had a lesion 
detectable on US too. After a mammographically controlled 
GWL, 4 of this group had malignant pathology and one was 
atypical ductal hyperplasia (ADH). Out of the 7 which did not 
reveal a lesion on US only one had an abnormal pathology of 
atypical ductal hyperplasia after mammographic GWL.
Figure 2 shows the relative distribution of the mammogram 
GWL breast lesions. Fifty-one (45.9%) lesions were located in 
the upper outer quadrants. In this cohort, histologically, 43 of 
these suspicious non palpable lesions were malignant and 4 were 
reported as atypical ductal hyperplasia. For statistical purposes 
therefore, this cohort had 47 abnormal lesions (42.3%). Twenty-
three (48.9%) with abnormal pathology were located in the 
upper outer quadrants but this was not statistically significant. 
This cohort of patients had a true positive rate of 42.3% and a 
false positive rate of 55.6%.
US GWL group
Twenty patients (80%) of this cohort of 25 patients also had 
a mammogram performed. A non palpable breast lesion was 
also evident on the mammogram in 8 of this group of patients. 
Thus 32% of the US GWL group had lesions evident on both 
radiological modalities. Four (16%) of all these suspicious non 
palpable breast lesions were malignant on histology. Therefore 
GWL: Guide wire localizations, US: ultrasound, Mammo: mammography
Table 1: Guide wire localization: patients and numbers
US GWL Mammo GWL Total
Patients (n) 25 (19.8%) 101 (80.2%) 126
GWLs (n) 25 (18.3%) 111 (81.6%) 136
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Table 2: Patient characteristics 
Patient characteristic US GWL Mammo GWL p
Age range (yrs)                           23-78        36-86
Mean age (yrs)                 44.9 (48)          56.02 (56) 0.009
Mean menarche age (yrs)                                               12.8     12.43 ns
Premenopausal                           2 (48%)*     20 (15.8%)* 0.008
Postmenopausal     13 (52%) *     81 (86.2%) * 0.002
Mean no. of children                    1.64              2.05 ns
Mean age of 1st pregnancy (yrs)      20.4 (24)        17.8 (21.5)     ns
Mean age of last pregnancy (yrs)               22.18 (28)           23 (28.5) ns
No. of patients that breast fed       4 (16%)*      19 (16.8%)* ns
Breast feeding duration (months)       1-9      2-48
Oral contraceptive users                             5 (20%)* 5 (5%)* 0.02
Range of duration of use (months)        3-120 3-60
Hormone replacement therapy                      1 (4%)* 12 (11.8%)* ns
Range of duration of use (months) 4-36 3-120
Smokers 15 (60%)* 13 (12.9%)* <0.001
Alcohol ingestion              4 (16%)* 7 (6.9%)* ns
Total abdominal hysterectomy & bilateral salpingo-oophorectomy 2 (8%)* 17 (16.8%)* ns
Total abdominal hysterectomy only            0 7 (6.9%)* ns
Bilateral salpingo-oophorectomy only               0 2(2%)* ns
Family history of breast cancer               4 (16%)* 32 (31.7%)* ns
Maternal family history 4 (16%)* 30 (25,7%)* ns
Paternal family history 0 2 (2%)* ns
Bilateral family history 0 1 (1%)* ns
Family history of ovarian cancer               1 (4%)* 2 (2%)* ns
Family history of colon cancer               0 2 (2%)* ns
The numbers in brackets are medians. The values in brackets marked with an asterisk represent percentage of that cohort
this cohort of patients had a true positive rate of 16% and a 
false positive rate of 84%. Figure 3 shows the distribution of 
the US GWL breast lesions in the different areas of the breast. 
There were more left sided lesions then right (14 versus 11) 
and 16 (64%) were located in the upper outer quadrant. Of the 
4 US detected breast lesions that were malignant 3 (75%) were 
located in the upper outer quadrant but this was not statistically 
significant. Three of these malignant lesions were on the left and 
the fourth on the right side (Figure 4 ).
Positive predictive rates and 
false positive rates
Table 4 shows the positive predictive value (true positive 
rate) for US and mammographically demonstrable non palpable 
breast lesions separately and the overall or total results of both 
modalities together with the 95% confidence intervals. False 
positive rates as a percentage for the two imaging modalities 
and the total or overall rate are depicted in Table 5. The chance 
that a suspicious lesion on US would be benign was estimated 
Table 3: Clinical features 
US GWL (n=25) Mammo GWL (n=101) p
Breast pain             5 (20%) 5 (4.9%) 0.02
Skin changes            1 (4%) 3 (2.9%) ns
Palpable breast lump 5 (20%) 8 (7.9%) ns
Palpable lymph nodes 1 (4%) 1 (0.9%) ns
US GWL: ultrasound detected group. Mammo GWL: mammography detected group
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to be 84%, while on mammography this was calculated to be 
57.6%, with an overall false positive rate of 62.5%.
Discussion
More than 600,000 women undergo breast biopsies 
annually worldwide and 20-40% of these are for non palpable 
breast lesions.1 Denning et al reported that 20% of non palpable 
breast lesions are malignant.2 Elmore JG et al performed a one 
year study of breast screening. 23.8% of these women had false 
positve mammograms.3
Our local cohort had an overall true positive rate of 37.5% 
and a false positive rate of 62.5%. The latter figure is well above 
figures in other centres. This is an important issue as a high 
false positive rate leads to both personal and national economic 
costs, as well as psychological and emotional upheaval. Indeed, 
a study on 1450 patients who had received a false positive result 
revealed that these patients were more likely to report feelings of 
sadness, restlessness and worthlessness.4 False positive results 
may also influence further management of these patients. At best 
a false positive result may lead to a follow up mammogram. At 
worst it can lead to a cascade of events ranging from biopsy to 
mastectomy.
Various studies have shown that both patient dependent and 
radiologist dependent factors may influence the false positive 
rate of screen mammograms.
Premenopausal state and young age and history of previous 
breast biopsy may contribute to increased breast density and 
may account for uncertainities in reporting. After adjusting for 
Table 4: Positive predicted value for ultrasound 
and mammography modalities
US Mammo Total
Positive predicted 
value %
16.0 42.3 37.5
LCI 5.3 33.1 29.5
UCI 36.9 52.1 46.2
Table 5: Percentage false positive rate of individual and 
combined modalities
False positive rate  US GWL Mammo GWL Total
%  84 57.6 62.5
LCI  64 48.0 55.0
UCI  95 67.0 72.5
Elmore JG et al reported an average false positive rate in the USA of 23.8% 
on mammography alone 3
Figure 1: Annual Guide Wire Localisations (GWL) 
for the period 2000-7
US GWL: ultrasound detected group. Mammo GWL: mammography 
detected group
Figure 3: Distribution of Suspicious Non Palpable 
Breast Lesion on US
Figure 2: Distribution of Suspicious Lesions 
on Mammo GWL
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Figure 4: Distribution of Malignant Lesions versus 
Benign Lesions in the US GWL group
patient characteristics radiologists have been shown to have a 
false positive rate ranging from 1.5% to 24.1%.
This inter-radiologist variability was related to inexperience 
in mammogram interpretation and other unmeasureable 
factors which accounted for 90% of the between – radiologist 
variance.5
Radiologists who spend more than 20% of their time reading 
mammograms have a sensitivity of 80% relative to 70% of their 
peers who spent less time. This is associated with false positive 
rates of 4.6% and 3.9% respectively.6
The number of radiologists working at Mater Dei is below the 
recommended staff levels and they are not dedicated to breast 
imaging. This applies to an even greater extent to those working 
in private clinics. Once a national breast screening programme 
is introduced there will be the advantage of screening being 
carried out in a single unit by a dedicated breast team with 
strict quality control.
Imaging should be done by two dedicated breast radiologists. 
Improved training in the different breast imaging modalities has 
also been encouraged in several papers.
The local high false positive rate increases workload, 
operating times, national health costs and the associated socio-
economic impact. Furthermore, the patient undergoes the 
procedure under general anaesthesia with associated morbidity 
and mortality. This raises two important points. The first is 
that women undergoing screening mammography should be 
informed of the possibilities of false positive results.
 The fact that further invasive or non-invasive tests may 
be necessary should be made clear to minimise anxiety and 
to encourage them to undergo further tests if necessary. The 
awareness of false positivity is also an essential medico-legal 
issue. The second point is that the introduction of minimally 
invasive biopsy procedures should be encouraged as these can 
be done in the imaging department under local anaesthesia 
and/or minimal sedation on an outpatient basis. Such biopsy 
procedures are also associated with less breast deformity, lower 
morbidity, lower costs and minimises on theatre time. With the 
imminent introduction of stereotactic equipment any woman 
having a suspicious lesion will avoid an invasive GWL but 
instead will undergo simply a minimally invasive stereotactic 
biopsy.
The authors feel that this study is important as it provides 
a baseline against which the audited results of the recently 
introduced National Breast Screening Programme can be 
compared in the future.
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